leadf
logo-loader
viewSensyne Health PLC

Sensyne Health highlight database growth and key product launches, set to drive 2021 growth

Sensyne Health PLC's (LON:SENS) Paul Drayson talks to Proactive London's Katie Pilbeam about the highlights from their latest report which includes growing their patient database to over 6.8m records.

He goes on to point out the new commercial agreements signed with the likes of industry heavyweights Bristol Myers Squibb and Alexion.

Added to this Drayson is pleased with the development and launch some key products.

Total revenues for the six months ended October 31, 2020, were £2.3mln; R&D costs were £7.7mln, giving a loss from operations of £9.5mln.

Quick facts: Sensyne Health PLC

Price: 179.9999 GBX

AIM:SENS
Market: AIM
Market Cap: £286.35 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Sensyne Health PLC named herein, including the promotion by the Company of Sensyne Health PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Market Report: FTSE marches into Spring ahead of crucial budget week

FTSE 100 started March in rollicking form as bond and equity markets settled after the recent sell-off. London’s leading index jumped 125 points to 6,608 in early trading.   Halfords Group PLC (LON:HFD) expects full-year profits to nearly double thanks to continued strong demand for...

2 days, 1 hour ago

2 min read